Asim Amin

7.2k citations

73 papers · 3.4k indexed · 1 hit paper · h-index 27

Impact in

Oncology top 1%
- Cancer Immunotherapy and Biomarkers
- CAR-T cell therapy research
- Lung Cancer Research Studies
Immunology top 2%
- Immunotherapy and Immune Responses
- Immune Cell Function and Interaction

Papers in

Oncology 55
- Cancer Immunotherapy and Biomarkers 41
- CAR-T cell therapy research 23
- Pancreatic and Hepatic Oncology Research 9
Pulmonary and Respiratory Medicine 26
- Renal cell carcinoma treatment 20

Co-authors: Jeryl Villadolid Hans J. Hammers Steven O’Day David F. McDermott Brian I. Rini Jeffrey S. Weber Elizabeth R. Plimack Sumanta K. Pal
Journals: Journal of Clinical Oncology (31 papers)Journal for ImmunoTherapy of Cancer (4 papers)Cancer Immunology Immunotherapy (3 papers)Familial Cancer (2 papers)Cancer Research (2 papers)
Partner nations: United States Germany Canada

In The Last Decade

Asim Amin

72 papers receiving 3.4k citations

Hit Papers

align trajectories log scale

Safety and Efficacy of Nivolumab in Combination With Ipilimumab in Metastatic Renal Cell Carcinoma: The CheckMate 016 Study 2017 · 348 citations

Peers

Countries citing papers authored by Asim Amin

Since Specialization

Citations

This map shows the geographic impact of Asim Amin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Asim Amin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Asim Amin more than expected).

Fields of papers citing papers by Asim Amin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Asim Amin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Asim Amin. The network helps show where Asim Amin may publish in the future.

Co-authors

The 25 scholars most cited alongside Asim Amin, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Asim Amin Line = papers co-authored together Asim Amin links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Hemophagocytic lymphohistiocytosis induced by dabrafenib-trametinib in a patient with metastatic melanoma: a case report and pharmacovigilance analysis Melanoma Research ·Joseph B. Elmes, Jessica Davis, Laura W. Musselwhite, Zane Chiad, Donald C. Moore, Asim Amin	2024	0
2	Nivolumab monotherapy or combination with ipilimumab with or without cobimetinib in previously treated patients with pancreatic adenocarcinoma (CheckMate 032) Journal for ImmunoTherapy of Cancer ·Margaret K. Callahan, Asim Amin, Frederic J. Kaye, Michael A. Morse, Matthew H. Taylor, Katriina Peltola, Padmanee Sharma, Eileen M. O’Reilly, Stephanie Meadows Shropshire, Shaun O’Brien, Marina Tschaika, Dung T. Le	2024	7
3	The Immunogenomic Landscape of Peripheral High-Dose IL-2 Pharmacodynamics in Patients with Metastatic Renal Cell Carcinoma: A Benchmark for Next-Generation IL-2–Based Immunotherapies The Journal of Immunology ·Kirk D. Beebe, Joel R. Eisner, Yuelong Guo, Yoichiro Shibata, James M. Davison, Josh Uronis, Carol Farhangfar, Farhang Farhangfar, Jill M. Mooney, Michael V. Milburn, Richard L. White, Asim Amin, Marcos E. Milla, David Foureau	2024	2
4	Clinical outcomes of adjuvant nivolumab in resected stage III melanoma: comparison of CheckMate 238 trial and real-world data Cancer Immunology Immunotherapy ·Justin C. Moser, Shailender Bhatia, Asim Amin, Anna C. Pavlick, Keith A. Betts, Ella X. Du, Tayla Poretta, Karishma Shelley, Swetha Srinivasan, Leon A. Sakkal, Jennell Palaia, Maurice Lobo, Melanie Pe Benito, Joshua A. Linton, Yan Chen, Churong Xu, Lei Yin, Manasvi Sundar, Jeffrey S. Weber	2024	1
5	Distinct Predictive Immunogenomic Profiles of Response to Immune Checkpoint Inhibitors and IL2: A Real-world Evidence Study of Patients with Advanced Renal Cancer Cancer Research Communications ·Joel R. Eisner, Kirk D. Beebe, Gregory M. Mayhew, Yoichiro Shibata, Yuelong Guo, Carol Farhangfar, Farhang Farhangfar, Joshua M. Uronis, Jill M. Mooney, Michael V. Milburn, David Foureau, Richard L. White, Asim Amin, Marcos E. Milla	2022	1
6	Long-Term Progression-Free Survival of Patients with Metastatic Melanoma or Renal Cell Carcinoma following High-Dose Interleukin-2 Journal of Investigative Medicine ·Joseph I. Clark, Brendan D. Curti, Elizabeth J. Davis, Howard L. Kaufman, Asim Amin, Ajjai Alva, Theodore F. Logan, Ralph J. Hauke, Gerald Miletello, Ulka N. Vaishampayan, Douglas B. Johnson, Richard L. White, Peter H. Wiernik, Janice P. Dutcher	2021	15
7	Venous thromboembolism incidence and risk factors in non-small cell lung cancer patients receiving first-line systemic therapy Thrombosis Research ·Hailey Hill, Myra Robinson, Lauren Xiaoyuan Lu, Daniel Slaughter, Asim Amin, Kathryn F. Mileham, Jai N. Patel	2021	24
8	Spectrum and prevalence of BRCA1/2 germline mutations in Pakistani breast cancer patients: results from a large comprehensive study Hereditary Cancer in Clinical Practice ·Muhammad Usman Rashid, Noor Muhammad, Humaira Naeemi, Faiz Ali Khan, Mariam Hassan, Saima Faisal, Sidra Gull, Asim Amin, Asif Loya, Ute Hamann	2019	26
9	Flexible Sigmoidoscopy Rather than Colonoscopy Is Adequate for the Diagnosis of Ipilimumab-Associated Colitis Southern Medical Journal ·John D. Herlihy, Stephen Beasley, Andrew Simmelink, Vinaya C. Maddukuri, Asim Amin, Michal Kamionek, Carl Jacobs, Krista Bossi, Martin Scobey	2019	14
10	Nivolumab Monotherapy and Nivolumab Plus Ipilimumab in Recurrent Small Cell Lung Cancer: Results From the CheckMate 032 Randomized Cohort Journal of Thoracic Oncology ·Neal Ready, Patrick A. Ott, Matthew D. Hellmann, Jon Zugazagoitia, Christine L. Hann, Filippo de Braud, Scott Antonia, Paolo A. Ascierto, Víctor Moreno, Akin Atmaca, Stefania Salvagni, Matthew H. Taylor, Asim Amin, D. Ross Camidge, Leora Horn, Emiliano Calvo, Ang Li, Wen Lin, Margaret K. Callahan, David R. Spigel	2019	218
11	SD-101 in Combination with Pembrolizumab in Advanced Melanoma: Results of a Phase Ib, Multicenter Study Cancer Discovery ·Antoni Ribas, Theresa Medina, Shivaani Kummar, Asim Amin, Anusha Kalbasi, Joseph J. Drabick, Minal Barve, Gregory A. Daniels, Deborah Jean Lee Wong, Emmett V. Schmidt, Albert F. Candia, Robert L. Coffman, Abraham C.F. Leung, Robert S. Janssen	2018	237
12	Safety and Efficacy of Nivolumab in Combination With Ipilimumab in Metastatic Renal Cell Carcinoma: The CheckMate 016 Study Journal of Clinical Oncology ·Hans J. Hammers, Elizabeth R. Plimack, Jeffrey R. Infante, Brian I. Rini, David F. McDermott, Lionel D. Lewis, Martin H. Voss, Padmanee Sharma, Sumanta K. Pal, Albiruni R. Abdul Razak, Christian Kollmannsberger, Daniel Y.C. Heng, Jennifer L. Spratlin, M. Brent McHenry, Asim Amin Hit paper breakdown →	2017	348
13	Phase II study of vemurafenib followed by ipilimumab in patients with previously untreated BRAF-mutated metastatic melanoma Journal for ImmunoTherapy of Cancer ·Asim Amin, David H. Lawson, April K.S. Salama, Henry Koon, Troy H. Guthrie, Sajeve Thomas, Steven O’Day, Montaser Shaheen, Bin Zhang, Stephen Francis, F. Stephen Hodi	2016	51
14	High prevalence and predominance of BRCA1 germline mutations in Pakistani triple-negative breast cancer patients BMC Cancer ·Muhammad Usman Rashid, Noor Muhammad, Seerat Bajwa, Saima Faisal, Muhammad Tahseen, Justo Lorenzo Bermejo, Asim Amin, Asif Loya, Ute Hamann	2016	28
15	Skin manifestations associated with kidney cancer Seminars in Oncology ·Asim Amin, Earle F. Burgess	2016	4
16	Randomized phase I pharmacokinetic study of ipilimumab with or without one of two different chemotherapy regimens in patients with untreated advanced melanoma. PubMed Central ·Jeffrey S. Weber, Omid Hamid, Asim Amin, Steven O’Day, Eric Masson, S. Goldberg, Daphne Williams, Susan Parker, Scott D. Chasalow, Suresh Alaparthy, Jedd D. Wolchok	2013	58
17	Prevalence of TP53 germ line mutations in young Pakistani breast cancer patients Familial Cancer ·Muhammad Usman Rashid, Sidra Gull, Kashif Asghar, Noor Muhammad, Asim Amin, Ute Hamann	2012	18
18	Safety and clinical activity of ipilimumab in melanoma patients with brain metastases Melanoma Research ·Jeffrey S. Weber, Asim Amin, David R. Minor, Jonathan Siegel, David M. Berman, Steven O’Day	2011	88
19	A Randomized, Double-Blind, Placebo-Controlled, Phase II Study Comparing the Tolerability and Efficacy of Ipilimumab Administered with or without Prophylactic Budesonide in Patients with Unresectable Stage III or IV Melanoma Clinical Cancer Research ·Jeffrey S. Weber, John A. Thompson, Omid Hamid, David R. Minor, Asim Amin, Ilan G. Ron, Ruggero Ridolfi, Hazem Assi, Anthony Maraveyas, David M. Berman, Jonathan Siegel, Steven O’Day	2009	460
20	Prevalence of BRCA1 and BRCA2 mutations in Pakistani breast and ovarian cancer patients International Journal of Cancer ·Muhammad Usman Rashid, Anbreen Zaidi, Diana Torres, Faisal Sultan, Axel Benner, B. Naqvi, Abdul Rauf Shakoori, Antje Seidel‐Renkert, Humirah Farooq, Steven A. Narod, Asim Amin, Ute Hamann	2006	89

About Asim Amin

Asim Amin is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Immunology, Cancer Research and Internal Medicine, having authored 73 papers that have together received 3.4k indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (41 papers), CAR-T cell therapy research (23 papers), Renal cell carcinoma treatment (20 papers), Immunotherapy and Immune Responses (14 papers), Cancer Genomics and Diagnostics (10 papers), BRCA gene mutations in cancer (9 papers), Pancreatic and Hepatic Oncology Research (9 papers) and Melanoma and MAPK Pathways (7 papers). The work is most often cited by research in Oncology (2.6k citations), Immunology (1.1k citations), Pulmonary and Respiratory Medicine (1.1k citations), Cancer Research (431 citations) and Molecular Biology (905 citations). Asim Amin has collaborated with scholars based in United States, Germany and Canada. Frequent co-authors include Jeryl Villadolid, Hans J. Hammers, Steven O’Day, David F. McDermott, Brian I. Rini, Jeffrey S. Weber, Elizabeth R. Plimack, Sumanta K. Pal, Christian Kollmannsberger and Jennifer L. Spratlin. Their work appears in journals such as Journal of Clinical Oncology, Journal for ImmunoTherapy of Cancer, Cancer Immunology Immunotherapy, Familial Cancer and Cancer Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact